FitLife Brands (FTLF) Competitors

FitLife Brands logo
$15.70 +0.44 (+2.85%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FTLF vs. AUTL, PHAR, HUMA, MNMD, XERS, ANAB, RNAC, TRDA, ERAS, and MLYS

Should you be buying FitLife Brands stock or one of its competitors? The main competitors of FitLife Brands include Autolus Therapeutics (AUTL), Pharming Group (PHAR), Humacyte (HUMA), Mind Medicine (MindMed) (MNMD), Xeris Biopharma (XERS), AnaptysBio (ANAB), Cartesian Therapeutics (RNAC), Entrada Therapeutics (TRDA), Erasca (ERAS), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry.

FitLife Brands vs.

Autolus Therapeutics (NASDAQ:AUTL) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.

FitLife Brands has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autolus Therapeutics$1.70M306.79-$208.38M-$1.21-1.62
FitLife Brands$52.70M1.37$5.30M$1.699.29

Autolus Therapeutics currently has a consensus price target of $10.40, suggesting a potential upside of 430.61%. FitLife Brands has a consensus price target of $20.00, suggesting a potential upside of 27.39%. Given Autolus Therapeutics' higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than FitLife Brands.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
FitLife Brands
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

FitLife Brands has a net margin of 13.38% compared to Autolus Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 28.03% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Autolus TherapeuticsN/A -63.65% -36.54%
FitLife Brands 13.38%28.03%15.13%

Autolus Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, FitLife Brands has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 61.3% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Autolus Therapeutics received 225 more outperform votes than FitLife Brands when rated by MarketBeat users. Likewise, 67.96% of users gave Autolus Therapeutics an outperform vote while only 50.00% of users gave FitLife Brands an outperform vote.

CompanyUnderperformOutperform
Autolus TherapeuticsOutperform Votes
227
67.96%
Underperform Votes
107
32.04%
FitLife BrandsOutperform Votes
2
50.00%
Underperform Votes
2
50.00%

In the previous week, FitLife Brands had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 4 mentions for FitLife Brands and 2 mentions for Autolus Therapeutics. FitLife Brands' average media sentiment score of 0.84 beat Autolus Therapeutics' score of -0.04 indicating that FitLife Brands is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Autolus Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
FitLife Brands
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

FitLife Brands beats Autolus Therapeutics on 12 of the 19 factors compared between the two stocks.

Get FitLife Brands News Delivered to You Automatically

Sign up to receive the latest news and ratings for FTLF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FTLF vs. The Competition

MetricFitLife BrandsMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$72.38M$1.19B$5.67B$9.04B
Dividend YieldN/AN/A5.31%4.00%
P/E Ratio9.2937.7890.3619.28
Price / Sales1.375.811,036.8679.91
Price / Cash19.3910.8846.0938.87
Price / Book2.581.815.135.00
Net Income$5.30M-$53.22M$113.24M$222.75M
7 Day Performance2.45%-4.84%-0.98%-0.57%
1 Month Performance5.48%-1.82%4.19%3.01%
1 Year Performance42.73%-12.67%21.69%17.84%

FitLife Brands Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FTLF
FitLife Brands
4.3739 of 5 stars
$15.70
+2.9%
$20.00
+27.4%
+35.6%$72.38M$52.70M9.2920Stock Split
Short Interest ↑
AUTL
Autolus Therapeutics
2.9025 of 5 stars
$2.11
-4.5%
$10.40
+392.9%
-70.1%$561.46M$10.09M-1.74330Short Interest ↑
PHAR
Pharming Group
3.1092 of 5 stars
$8.20
-6.4%
$27.00
+229.3%
-23.6%$557.85M$245.32M-31.54280Short Interest ↓
HUMA
Humacyte
3.2113 of 5 stars
$4.30
-6.1%
$13.71
+218.9%
+10.5%$541.20M$1.57M-3.21150Short Interest ↓
Gap Down
MNMD
Mind Medicine (MindMed)
2.1929 of 5 stars
$7.37
+8.5%
$26.33
+257.3%
+86.6%$540.44MN/A-3.2640Gap Down
XERS
Xeris Biopharma
3.7482 of 5 stars
$3.59
+0.8%
$5.15
+43.5%
+24.0%$535.20M$163.91M-7.98290Positive News
Gap Down
ANAB
AnaptysBio
3.8384 of 5 stars
$16.66
-7.1%
$41.45
+148.8%
-46.2%$506.96M$17.16M-2.74100Short Interest ↓
Trading Halted
RNAC
Cartesian Therapeutics
2.5759 of 5 stars
$19.89
+3.0%
$42.86
+115.5%
-9.2%$505.60M$26M-0.3864Analyst Revision
Positive News
TRDA
Entrada Therapeutics
3.2501 of 5 stars
$13.33
-0.8%
$25.67
+92.5%
-19.1%$498.81M$129.01M8.38110
ERAS
Erasca
2.5798 of 5 stars
$1.76
-6.9%
$5.70
+223.9%
-14.1%$497.61MN/A-2.12120
MLYS
Mineralys Therapeutics
2.8095 of 5 stars
$9.93
-3.6%
$30.00
+202.1%
-34.4%$494.22MN/A-3.0428Earnings Report
News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:FTLF) was last updated on 2/12/2025 by MarketBeat.com Staff
From Our Partners